Amgen Inc. Stock (US0311621009): Morgan Stanley Raises Price Target to $326

Morgan Stanley raised its price target on Amgen Inc. (NASDAQ:AMGN) from $309 to $326 while maintaining an 'equal weight' rating, according to a research note issued on April 28, 2026. The stock traded at $342.74 on the NASDAQ on April 28, 2026.

Morgan Stanley raised its price target on Amgen Inc. (NASDAQ:AMGN) from $309 to $326 while maintaining an "equal weight" rating, according to a research note issued on Tuesday, April 28, 2026. The stock traded up $2.56 during trading hours on April 28, 2026, reaching $342.74 on the NASDAQ.

As of: Thursday, April 30, 2026

By the AD HOC NEWS Editorial Team – Equity Coverage.

At a Glance

• Name: Amgen
• ISIN: US0311621009
• Sector/Industry: Healthcare / Biotechnology
• Headquarters/Country: Thousand Oaks, California, United States
• Primary Exchange: NASDAQ
• Trading Currency: USD
• Next Earnings Date: 04/30/26 [AMC]
• Next Ex-Dividend Date: 05/15/26

How Amgen Inc. Makes Money: The Core Business Model

Amgen Inc. generates revenue primarily through the development, manufacturing, and commercialization of human therapeutics based on biotechnology. The company focuses on areas such as oncology, inflammation, immunology, rare diseases, and cardiovascular disease. Its business model relies on a portfolio of proprietary products sold globally, with significant revenue from the United States market.

Amgen employs advanced biotechnology methods including recombinant DNA technology, cell culture processes, and protein purification to create biologic medicines. These products are distributed through direct sales forces, distributors, and strategic partnerships with other pharmaceutical companies. The company invests heavily in research and development to maintain its pipeline of innovative therapies.

Revenue streams are diversified across multiple therapeutic areas, with key products driving the majority of sales. Amgen also pursues strategic acquisitions and collaborations to expand its portfolio and market reach. The NASDAQ-listed company files regular reports with the U.S. Securities and Exchange Commission (SEC), providing transparency for US investors.

Amgen Inc.'s Key Revenue and Product Drivers

Amgen Inc. derives a substantial portion of its revenue from blockbuster biologic drugs targeting chronic diseases. Products in oncology and bone health have historically been major contributors, supported by global sales teams and manufacturing facilities in the United States and Europe. The company's focus on innovative therapies addresses unmet medical needs in high-prevalence conditions.

Recent quarterly results included adjusted EPS of $5.29 for the period ended December 31, 2025, published on February 3, 2026. Revenue for that quarter reached $9.87 billion, according to company disclosures. Amgen has provided FY 2026 guidance of adjusted EPS in the range of $21.60 to $23.00.

The company maintains a robust pipeline of investigational therapies across multiple modalities, including bispecific antibodies and small molecules. Strategic partnerships enhance product development and commercialization efforts, particularly in emerging markets outside the core US base.

Industry Trends and Competitive Landscape

The biotechnology sector continues to evolve with advances in gene therapy, cell therapy, and precision medicine. Amgen Inc. operates in a competitive environment where innovation cycles are accelerating, driven by regulatory approvals from the U.S. Food and Drug Administration (FDA). Market demand for biologics treating chronic and rare diseases supports long-term growth potential.

Key competitors in the oncology and immunology spaces include other major biotech firms with similar product portfolios. Industry reports highlight increasing consolidation through mergers and acquisitions as companies seek to bolster pipelines. Global spending on biologics is projected to expand, benefiting established players with strong US market presence.

Amgen Inc. differentiates through its expertise in protein-based therapeutics and a diversified revenue base. Challenges include patent expirations and the rise of biosimilars, which pressure pricing in mature markets like the United States.

Why Amgen Inc. Matters to US Investors

Amgen Inc. is listed on the NASDAQ under the ticker AMGN, trading in USD, which eliminates foreign exchange risk for US investors. The company generates a significant portion of its revenue from the United States, supported by SEC filings that provide detailed financial transparency. Inclusion in major indices like the S&P 500 offers exposure through index funds popular among retail investors.

The stock's dividend yield, based on an annual payout of approximately $10.08 forward, appeals to income-focused portfolios. Recent trading showed the shares at $342.74 on April 28, 2026, on the NASDAQ. US regulatory developments directly impact product approvals and market access for Amgen's portfolio.

For US investors, Amgen represents a blend of defensive healthcare exposure with growth from innovative therapies. Quarterly earnings and analyst updates, such as the recent Morgan Stanley note, provide regular catalysts amid broader market volatility.

Which Investor Profile Fits Amgen Inc. – and Which Does Not?

Amgen Inc. suits investors seeking stability in the healthcare sector with a history of dividend growth. Those prioritizing biologic innovation and exposure to chronic disease markets may find alignment with the company's focus areas. Long-term holders benefit from the firm's established US manufacturing and distribution infrastructure.

High-growth seekers focused solely on early-stage biotech may prefer smaller firms with higher risk profiles. Amgen's mature portfolio and dividend emphasis cater less to pure momentum traders. Patient capital with tolerance for regulatory and competitive pressures matches the profile best.

Institutional ownership stands at about 76.5% of shares, indicating confidence from large funds. Retail investors tracking NASDAQ biotech trends can monitor upcoming earnings for insights into pipeline progress.

What Analysts Are Saying About Amgen Inc. Stock

Analyst consensus rates Amgen Inc. as a "Hold," with a mean price target of $356.62 as of recent updates. One analyst rates it Strong Buy, fourteen Buy, fourteen Hold, and two Sell. Morgan Stanley's adjustment to $326 implies potential downside from recent levels around $342.74.

Risks and Open Questions for Amgen Inc.

Amgen Inc. faces risks from patent cliffs on key products, potentially leading to biosimilar competition. Regulatory hurdles for pipeline candidates could delay approvals from the FDA. Pricing pressures in the US market, amid healthcare reform discussions, impact margins.

Macroeconomic factors like inflation and interest rates affect R&D spending and acquisition strategies. Upcoming Q1 2026 earnings on April 30, 2026, after market close, will shed light on guidance execution. Competitive dynamics in oncology remain intense.

Geopolitical tensions could disrupt global supply chains for biologics manufacturing. Investors should watch ex-dividend date of May 15, 2026, for payout details.

Key Events and Outlook for Investors

Amgen Inc. reports Q1 2026 earnings on April 30, 2026, after market close. A conference call is typically held following the release. FY 2026 EPS guidance stands at $21.60–$23.00, compared to sell-side estimates around $22.16.

What to Watch Next

• 04/30/26 [AMC]: Q1 Earnings Release & Conference Call
• 05/15/26: Next Ex-Dividend Date

Conclusion

Morgan Stanley's price target increase to $326 on April 28, 2026, highlights ongoing analyst interest in Amgen Inc. amid upcoming Q1 earnings. The stock's position on the NASDAQ with USD trading and strong US revenue exposure remains relevant for American investors. Key events like the April 30 earnings release will provide further clarity on FY 2026 guidance execution.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.